Home

Barry E Greene

CIK 1291963 · President and CEO · last filed 2026-06-23

Barry E Greene is a President and CEO who has filed 107 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for DYN, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$58.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$15.71M

Companies

6

Total Filings

107

Lifetime Open-Market Net

-$58.92M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DYN Director — $26.00 — $0 1 2026-06-23
KPTI Director 16,415 $1.93 $31.7K $87.9K 16 2026-05-26
Sage Therapeutics, Inc. (SAGE) Delisted President and CEO 0 $8.68 $0 $2.02M 13 2025-07-31
Acorda Therapeutics, Inc. (ACOR) Delisted Director 83 $0.66 $55 -$290.2K 20 2021-06-04
ALNY President 68,588 $228.61 $15.68M -$60.74M 55 2020-09-11
Regulus Therapeutics Inc. (RGLS) Delisted Director 51,254 $8.16 $418.2K $0 2 2012-11-07

Recent Filings

107 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 DYN Grant (A) — $0 EDGAR
2026-05-26 KPTI Grant (A) +15,508 $0 EDGAR
2025-07-31 Sage Therapeutics, Inc. (SAGE) Delisted Mixed −100,169 $0 EDGAR
2025-05-29 KPTI Grant (A) — $0 EDGAR
2025-04-11 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +15,102 -$33.6K EDGAR
2025-01-21 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2024-08-07 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +38,127 -$110.0K EDGAR
2024-05-30 KPTI Grant (A) — $0 EDGAR
2024-02-15 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2023-08-08 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 107
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.